Ocular Toxicity of Iron Chelator Drugs among Thalassemia Patients; a Review
Journal of Ophthalmic and Optometric Sciences,
Vol. 1 No. 5 (2017),
23 September 2017
,
Page 31-36
https://doi.org/10.22037/joos.v1i5.27947
Abstract
Transfusion dependent thalassemia is a hematological condition characterized by imbalance in synthesis of alpha and beta subunits of hemoglobin. The consequence of regular and repeated transfusions is iron deposition in different organs. In order to survive, these patients need iron chelator drugs. The oldest drug of this group is desferrioxamine which is administered subcutaneously or intravenously. Nowadays, oral iron chelator drugs, including deferiprone, deferasirox are in more widespread use since they are more convenience to use. In this review the ocular toxicity of these chelator drugs is discussed.
keywords: Ocular; Toxicity; Iron chelating agents; Thalassemia.
How to Cite
References
- Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
- Hashemieh M, Timori Naghadeh H, Tabrizi Namini M, Neamatzadeh H, Hadipour Dehshal M. The Iran Thalassemia Prevention Program: Success or Failure?. Iran J Ped Hematol Oncol. 2015;5(3):161-6.
- Miri M, Tabrizi Namini M, Hadipour Dehshal M, Sadeghian Varnosfaderan, Ahmadvand A, Yousef Darestani S, et al. Thalassemia in Iran in Last Twenty Years: the Carrier Rates and the Births Trend. Iranian Journal of Blood and Cancer. 2013;1:11-8.
- Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233-8.
- Azarkeivan A, Hashemieh M, Shirkavand A, Sheibani K. Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran. Arch Iran Med. 2016;19(2):96-100.
- Hashemieh M, Radfar M, Azarkeivan A, Hosseini Tabatabaei SMT, Nikbakht S, Yaseri M, et al. Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res. 2017;11(2):133-8.
- Shah N, Mishra A, Chauhan D, Vora C, Shah NR. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian J Transfus Sci. 2010;4(2):94-8.
- Aksoy A, Aslankurt M, Aslan L, Gül Ö, Garipardıç M, Çelik O,et al. Ocular findings in children with thalassemia major in Eastern Mediterranean. Int J Ophthalmol. 2014;7(1):118-21.
- Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG, et al. β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol. 2016;16:102.
- Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50(2):99-104.
- Saliba AN, El Rassi F, Taher AT. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert Rev Hematol. 2016;9(2):151-68.
- Di Nicola M, Barteselli G, Dell'Arti L, Ratiglia R, Viola F. Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature. Biomed Res Int. 2015;2015:249617.
- Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239–47.
- Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM,et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2017;8(8):CD007476.
- Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28(6):894-9.
- Arora A, Wren S, Gregory Evans K. Desferrioxamine related maculopathy: a case report. Am J Hematol. 2004;76(4):386-8.
- Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS. Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012;60(4):315-7.
- Bhoiwala DL, Dunaief JL. Retinal abnormalities in β-thalassemia major. Surv Ophthalmol. 2016;61(1):33-50.
- Bui KM, Sadda SR, Salehi-Had H. Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity. Digit J Ophthalmol. 2017;23(1):11–5.
- Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica. 1991;76(2):131-4.
- Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3:795805.
- Hadziahmetovic M, Pajic M, Grieco S, Song Y, Song D, Li Y, et al. The Oral Iron Chelator Deferiprone Protects Against Retinal Degeneration Induced through Diverse Mechanisms. Transl Vis Sci Technol. 2012;1(3):2.
- Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S, Baz P. Ocular findings among thalassemia patients. Am J Ophthalmol. 2006;142(4):704-5.
- Mehdizadeh M, Nowroozzadeh MH. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption. Clin Exp Optom. 2009; 92(4): 392-4.
- Botzenhardt S, Li N, Chan EW, Sing CW, Wong IC, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol. 2017;98(3):198-217.
- Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol. 2010;58(2):125-30.
- Jafari R, Heydarian S, Karami H, et al. Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol. 2015;63(9):710–715. doi:10.4103/0301-4738.170986.
- Georgakopoulos CD, Tsapardoni F, Kostopoulou EV, Makri OE. Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. BMC Ophthalmol. 2018;18(1):246.
- Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013;2013:bcr2013009205.
- Merchant RH, Punde H, Thacker N, Bhatt D. Ophthalmic Evaluation in Beta-Thalassemia. Indian J Pediatr. 2017;84(7):509-14.
- Pan Y, Keane PA, Sadun AA, Fawzi AA. Optical coherence tomography findings in deferasirox-related maculopathy. Retin Cases Brief Rep. 2010;4(3):229-32.
- Wu CH, Yang CP, Lai CC, Wu WC, Chen YH. Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol. 2014;14:88.
- Masera N, Rescaldani C, Azzolini M, Vimercati C, Tavecchia L, Masera G, et al. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy. Haematologica. 2008;93(1):e9-10.
- Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS. Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012;60(4):315-7.
- Viola F, Barteselli G, Dell'arti L, Vezzola D, Villani E, Mapelli C. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology. 2012;119(8):1693-700.
- Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol. 1986;70(5):373-81.
- Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, et al. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica. 1991;76(2):131-4.
- Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephrol. 1989;31(1):45-8.
- Abstract Viewed: 161 times
- PDF Downloaded: 266 times
